Cancer Res Treat.  2014 Jul;46(3):312-316.

Cyclosporine A as a Primary Treatment for Panniculitis-like T Cell Lymphoma: A Case with a Long-Term Remission

Affiliations
  • 1Department of Internal Medicine, Institute of Health Sciences, Gyeongsang National University School of Medicine, Jinju, Korea. lwshmo@hanmail.net
  • 2Department of Pathology, Institute of Health Sciences, Gyeongsang National University School of Medicine, Jinju, Korea.

Abstract

Subcutaneous panniculitis-like T cell lymphoma (SPTL) is a distinctive cutaneous lymphoma characterized by an infiltration of subcutaneous tissue by neoplastic T cells, similar to panniculitis. It is well-established that patients who are diagnosed with SPTL usually respond poorly to chemotherapy, showing fatal outcome. As a first line treatment for SPTL, anthracycline-based chemotherapy was most frequently used. For the treatment of SPTL, the efficacy of cyclosporine A has been recently reported in relapsed SPTL after anthracycline-based chemotherapy. However, it is still not clear whether cyclosporine A can be used as a first-line treatment against SPTL. Here, we report a case of SPTL, which achieved complete remission for nine years after first-line cyclosporine A therapy. This study suggests that cyclosporine A can induce a complete long-term remission as a first-line treatment.

Keyword

Subcutaneous panniculitis-like T cell lymphoma; Cyclosporine A; Remission

MeSH Terms

Cyclosporine*
Drug Therapy
Fatal Outcome
Humans
Lymphoma
Lymphoma, T-Cell*
Panniculitis
Subcutaneous Tissue
T-Lymphocytes
Cyclosporine
Full Text Links
  • CRT
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error